{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:58:47Z","timestamp":1783007927961,"version":"3.54.5"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pnpbp.2018.03.016","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T18:45:39Z","timestamp":1521830739000},"page":"340-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Neurometabolite levels in antipsychotic-na\u00efve\/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies"],"prefix":"10.1016","volume":"86","author":[{"given":"Yusuke","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Plitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Mihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Caravaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ku","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-1333","authenticated-orcid":false,"given":"Julia","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gerretsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.yco.0000214337.29378.cd","article-title":"What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update","volume":"19","author":"Abbott","year":"2006","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0010","series-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0015","series-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1983"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0020","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1192\/bjp.bp.110.079608","article-title":"Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia","volume":"198","author":"Aoyama","year":"2011","journal-title":"British J. Psychiatry Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mrm.1910320202","article-title":"Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations","volume":"32","author":"Barker","year":"1994","journal-title":"Magn. Reson. Med."},{"issue":"10","key":"10.1016\/j.pnpbp.2018.03.016_bb0030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/archpsyc.1997.01830220085012","article-title":"Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy","volume":"54","author":"Bartha","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2018.03.016_bb0035","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-3223(99)00007-4","article-title":"A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients","volume":"45","author":"Bartha","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0720-048X(99)00052-2","article-title":"Proton magnetic resonance spectroscopy in schizophrenia","volume":"30","author":"Bertolino","year":"1999","journal-title":"Eur. J. Radiol."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0045","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/mrm.25331","article-title":"Lipid suppression for brain MRI and MRSI by means of a dedicated crusher coil","volume":"73","author":"Boer","year":"2015","journal-title":"Magn. Reson. Med."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.03.016_bb0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2016.02.017","article-title":"Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a (1)H MRS study at 7Tesla","volume":"172","author":"Brandt","year":"2016","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.03.016_bb0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopsych.2012.06.023","article-title":"A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder","volume":"73","author":"Brennan","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.03.016_bb0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopsych.2010.10.004","article-title":"Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis","volume":"69","author":"Brugger","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.03.016_bb0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.159.1.130","article-title":"High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia","volume":"159","author":"Bustillo","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0893-133X(98)00063-3","article-title":"Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia","volume":"20","author":"Cecil","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.pnpbp.2018.03.016_bb0075","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.biopsych.2007.05.025","article-title":"Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction","volume":"62","author":"Chang","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0003-4975(00)01088-2","article-title":"Joint statement on redundant (duplicate) publication by the editors of the undersigned cardiothoracic journals","volume":"69","author":"Cho","year":"2000","journal-title":"Ann. Thorac. Surg."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.03.016_bb0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1076-6332(05)80716-0","article-title":"1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia","volume":"1","author":"Choe","year":"1994","journal-title":"Acad. Radiol."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00004424-199606000-00006","article-title":"Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy","volume":"31","author":"Choe","year":"1996","journal-title":"Investig. Radiol."},{"issue":"4\u20136","key":"10.1016\/j.pnpbp.2018.03.016_bb0095","first-page":"365","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.03.016_bb0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2014.05.004","article-title":"Prefrontal glutamate levels differentiate early phase schizophrenia and methamphetamine addiction: a (1)H MRS study at 3\u202fTesla","volume":"157","author":"Crocker","year":"2014","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2018.03.016_bb0105","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/npp.2011.65","article-title":"Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis","volume":"36","author":"de la Fuente-Sandoval","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2018.03.016_bb0110","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","article-title":"Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study","volume":"70","author":"de la Fuente-Sandoval","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.03.016_bb0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/mrm.21234","article-title":"In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3\u202fTesla","volume":"57","author":"Edden","year":"2007","journal-title":"Magn. Reson. Med."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.03.016_bb0130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mrm.24391","article-title":"Macromolecule-suppressed GABA-edited magnetic resonance spectroscopy at 3T","volume":"68","author":"Edden","year":"2012","journal-title":"Magn. Reson. Med."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.124","article-title":"Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis","volume":"7","author":"Egerton","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"7109","key":"10.1016\/j.pnpbp.2018.03.016_bb0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0145","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0150","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0006-3223(03)00185-9","article-title":"Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia","volume":"54","author":"Fannon","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.pnpbp.2018.03.016_bb0155","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/0006-3223(95)00046-1","article-title":"Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?","volume":"38","author":"Farber","year":"1995","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.03.016_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pscychresns.2014.04.010","article-title":"Atypical antipsychotic drug treatment for 6\u202fmonths restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: a magnetic resonance spectroscopy study","volume":"223","author":"Gan","year":"2014","journal-title":"Psychiatry Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2018.03.016_bb0165","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.pnpbp.2010.08.007","article-title":"No alterations of brain GABA after 6\u202fmonths of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia","volume":"34","author":"Goto","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0170","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.03.016_bb0175","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/schbul\/sbs118","article-title":"Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects","volume":"39","author":"Haijma","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/npjschz.2016.33","article-title":"Alterations in the hippocampus and thalamus in individuals at high risk for psychosis","volume":"2","author":"Harrisberger","year":"2016","journal-title":"NPJ Schizophr."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0185","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1751-7893.2011.00291.x","article-title":"Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naive schizophrenia patients","volume":"6","author":"He","year":"2012","journal-title":"Early Intervent. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.03.016_bb0195","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archgenpsychiatry.2011.1519","article-title":"Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy","volume":"69","author":"Kegeles","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pnpbp.2013.07.024","article-title":"Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex","volume":"47","author":"Kelemen","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.03.016_bb0205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hup.693","article-title":"A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies","volume":"20","author":"Kim","year":"2005","journal-title":"Hum. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.03.016_bb0210","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J. Clin. Epidemiol."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2018.03.016_bb0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pscychresns.2012.02.003","article-title":"Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis","volume":"203","author":"Kraguljac","year":"2012","journal-title":"Psychiatry Res."},{"issue":"12","key":"10.1016\/j.pnpbp.2018.03.016_bb0220","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamapsychiatry.2013.2437","article-title":"Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia","volume":"70","author":"Kraguljac","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/nbm.891","article-title":"Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts","volume":"17","author":"Kreis","year":"2004","journal-title":"NMR Biomed."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.03.016_bb0230","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0235","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/7854_2011_197","article-title":"MR spectroscopic studies of the brain in psychiatric disorders","volume":"11","author":"Maddock","year":"2012","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.03.016_bb0240","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1176\/appi.ajp.2015.15020190","article-title":"Prefrontal GABA levels measured with magnetic resonance spectroscopy in patients with psychosis and unaffected siblings","volume":"173","author":"Marenco","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.03.016_bb0245","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/schbul\/sbr069","article-title":"Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies","volume":"39","author":"Marsman","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0250","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.nicl.2014.10.005","article-title":"GABA and glutamate in schizophrenia: a 7 T (1)H-MRS study","volume":"6","author":"Marsman","year":"2014","journal-title":"NeuroImage. Clin."},{"issue":"7","key":"10.1016\/j.pnpbp.2018.03.016_bb0255","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0260","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J","article-title":"Simultaneous in vivo spectral editing and water suppression","volume":"11","author":"Mescher","year":"1998","journal-title":"NMR Biomed."},{"issue":"10","key":"10.1016\/j.pnpbp.2018.03.016_bb0265","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2018.03.016_bb0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2004.08.021","article-title":"Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study","volume":"73","author":"Ohrmann","year":"2005","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2018.03.016_bb0275","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jpsychires.2006.07.002","article-title":"Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study","volume":"41","author":"Ohrmann","year":"2007","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.03.016_bb0280","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pscychresns.2008.06.002","article-title":"Creatine abnormalities in schizophrenia and bipolar disorder","volume":"172","author":"Ongur","year":"2009","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2018.03.016_bb0285","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.biopsych.2010.05.016","article-title":"Elevated gamma-aminobutyric acid levels in chronic schizophrenia","volume":"68","author":"Ongur","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0290","article-title":"CSF GABA is reduced in first-episode psychosis and associates to symptom severity","author":"Orhan","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0295","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0300","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/schbul\/sbv118","article-title":"Elevated Myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients with first-episode psychosis: a proton magnetic resonance spectroscopy study with implications for glial dysfunction","volume":"42","author":"Plitman","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.pnpbp.2018.03.016_bb0305","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/mp.2016.258","article-title":"Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum","volume":"22","author":"Roalf","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.03.016_bb0310","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/schbul\/sbs092","article-title":"In vivo measurements of glutamate, GABA, and NAAG in schizophrenia","volume":"39","author":"Rowland","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.03.016_bb0315","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/mp.2015.34","article-title":"Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study","volume":"21","author":"Rowland","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2018.03.016_bb0320","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/hbm.23244","article-title":"Brain GABA levels across psychiatric disorders: a systematic literature review and meta-analysis of (1) H-MRS studies","volume":"37","author":"Schur","year":"2016","journal-title":"Hum. Brain Mapp."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.03.016_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jnc.12398","article-title":"Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies","volume":"128","author":"Schwerk","year":"2014","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.03.016_bb0330","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/schbul\/22.4.597","article-title":"An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients","volume":"22","author":"Stanley","year":"1996","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.03.016_bb0335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2007.03.028","article-title":"Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study","volume":"93","author":"Stanley","year":"2007","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.03.016_bb0340","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0269881106073126","article-title":"Glutamate and dopamine dysregulation in schizophrenia\u2014a synthesis and selective review","volume":"21","author":"Stone","year":"2007","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"issue":"4","key":"10.1016\/j.pnpbp.2018.03.016_bb0345","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-0031-1279739","article-title":"Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment","volume":"44","author":"Szulc","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.03.016_bb0350","first-page":"414","article-title":"Proton magnetic resonance spectroscopy changes after antipsychotic treatment","volume":"20","author":"Szulc","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.03.016_bb0355","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.schres.2014.10.011","article-title":"GABA abnormalities in schizophrenia: a methodological review of in vivo studies","volume":"167","author":"Taylor","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.03.016_bb0360","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2009.11.011","article-title":"GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study","volume":"117","author":"Tayoshi","year":"2010","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.03.016_bb0365","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.biopsych.2016.04.007","article-title":"7T proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings","volume":"81","author":"Thakkar","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2018.03.016_bb0370","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1176\/appi.ajp.159.11.1944","article-title":"Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers","volume":"159","author":"Theberge","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.03.016_bb0375","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.bp.106.033670","article-title":"Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia","volume":"191","author":"Theberge","year":"2007","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.03.016_bb0380","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mrm.24291","article-title":"3-T proton magnetic spectroscopy in unmedicated first episode psychosis: a focus on creatine","volume":"69","author":"Tibbo","year":"2013","journal-title":"Magn. Reson. Med."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.03.016_bb0385","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.schres.2008.03.012","article-title":"A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis","volume":"102","author":"Wood","year":"2008","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.pnpbp.2018.03.016_bb0390","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1523\/JNEUROSCI.6158-09.2010","article-title":"GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression","volume":"30","author":"Yoon","year":"2010","journal-title":"J. Neurosci."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618300393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618300393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:48:47Z","timestamp":1759520927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584618300393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":78,"alternative-id":["S0278584618300393"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.03.016","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurometabolite levels in antipsychotic-na\u00efve\/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}